INSURERS REJECT Trump’s Weight-Loss Plan!

Doctor filling syringe with vaccine from vial.

Medicare will soon cap seniors’ out-of-pocket costs for popular weight-loss drugs at $50 a month—thanks to Trump’s hard-nosed pricing deals—despite insurers walking away and a decades-old law that tried to block coverage.

Story Highlights

White House secured $245/month “most-favored nation” pricing for GLP-1 drugs, yielding a $50 senior copay.
Insurers refused to join the BALANCE pilot, citing financial risk; CMS canceled the pilot.
CMS will launch a Medicare-funded “GLP-1 Bridge” in July 2026 through 2027 to keep $50 access.
Coverage uses demonstration authority to bypass Medicare’s statutory weight-loss drug ban.

Trump’s Price Deal Breaks a 20-Year Medicare Logjam

President Donald Trump announced in November 2025 that his team locked in “most-favored nation” pricing with Eli Lilly and Novo Nordisk, dropping Medicare and Medicaid prices for drugs like Wegovy and Zepbound to $245 per month. The deal undercut prior proposals and opened the door to obesity coverage that Medicare’s 2003 law forbids. The administration paired the discounts with a $50 copay promise for eligible seniors, arguing lower prices and better health outcomes would save taxpayers money over time.

CMS designed the BALANCE model to test that claim inside Medicare Part D and Medicaid using its demonstration waiver authority. Officials targeted broad access with defined clinical criteria, including BMI thresholds and comorbidities such as prediabetes, heart disease, or hypertension. The model required major insurer participation to spread financial risk, collect outcomes data, and validate budget impacts. CMS circulated FAQs in early 2026 detailing prior authorization and the $50 copay for qualified beneficiaries under the pilot construct.

Insurers Balk, Forcing a Strategic Pivot to a Bridge Program

Health plans declined to join BALANCE by the April 20, 2026 deadline, warning that rapid uptake and high baseline spending would strain Part D finances. Without the required level of insurer commitment, CMS canceled the pilot. The agency immediately pivoted to a fully Medicare-funded “GLP-1 Bridge,” set to start in July 2026 and run through 2027. Under the Bridge, manufacturers provide eligible drugs to Medicare at the negotiated $245 net price, preserving the $50 senior copay while sidestepping insurer risk.

CMS framed the Bridge as a transitional path to gather utilization and outcomes data needed for a potential revival of a longer-term model. America’s Health Insurance Plans called the Bridge a logical step to ensure access and evaluate sustainability before embedding the benefit inside Part D. The Trump administration maintained that keeping seniors’ costs predictable honors the pricing victory and counters years of inflated list prices that pushed GLP-1s out of reach for people on fixed incomes.

Eligibility Rules, Copay Mechanics, and What Seniors Should Expect

Eligibility will track evidence-based criteria. Seniors generally qualify with a BMI of 27 or higher plus a related condition such as prediabetes or cardiovascular disease, a BMI above 30 with qualifying comorbidities like heart issues, hypertension, or chronic kidney disease, or a BMI above 35. Physicians must submit prior authorizations documenting clinical need. The $50 monthly copay will not apply to the Part D deductible or out-of-pocket maximums because the Bridge runs outside standard Part D structures.

That design means the $50 price is stable but does not help beneficiaries reach catastrophic thresholds. CMS and the White House argue that predictable low copays matter most for adherence and outcomes. The Bridge also enables data collection on weight loss, cardiovascular events, and diabetes progression. Those results could justify a permanent waiver model that offsets drug spending with downstream savings on heart disease and diabetes care, areas that already drive large Medicare costs.

Fiscal Tradeoffs, Legal Workarounds, and Conservative Guardrails

Medicare’s 2003 statute bans coverage of weight-loss drugs, but CMS can test waivers through demonstrations. The administration uses that authority to fill a gap while applying aggressive price leverage on manufacturers. The $245 price—far below $1,000-plus list prices—helps contain taxpayer exposure, yet total spending will rise if millions enroll quickly. Insurers’ refusal underscores that the financial risk is real; the Bridge shifts that risk to Medicare while evidence accumulates on long-term savings and health gains.

Conservatives should watch two fronts. First, accountability on program costs and fraud prevention is essential to protect taxpayers and seniors who rely on Medicare’s solvency. Second, the demonstration route must remain a targeted tool, not a backdoor for unrelated expansions or bureaucratic mission creep. The Trump administration’s approach ties access to strict clinical criteria, prior authorization, and enforceable manufacturer pricing—all consistent with limited-government principles that demand value for every public dollar.